Related Experiment Video
Updated: Jun 4, 2025
High-Efficiency Generation of Antigen-Specific Primary Mouse Cytotoxic T Cells for Functional Testing in an Autoimmune Diabetes Model
Published on: August 16, 2019
Leveraging artificial intelligence and machine learning to accelerate discovery of disease-modifying therapies in
Melanie R Shapiro1,2, Erin M Tallon3,4,5, Matthew E Brown1,2
1Department of Pathology, Immunology, and Laboratory Medicine, College of Medicine, University of Florida, Gainesville, FL, USA.
Abstract:
Progress in developing therapies for the maintenance of endogenous insulin secretion in, or the prevention of, type 1 diabetes has been hindered by limited animal models, the length and cost of clinical trials, difficulties in identifying individuals who will progress faster to a clinical diagnosis of type 1 diabetes, and heterogeneous clinical responses in intervention trials. Classic placebo-controlled intervention trials often include monotherapies, broad participant populations and extended follow-up periods focused on clinical endpoints. While this approach remains the 'gold standard' of clinical research, efforts are underway to implement new approaches harnessing the power of artificial intelligence and machine learning to accelerate drug discovery and efficacy testing. Here, we review emerging approaches for repurposing agents used to treat diseases that share pathogenic pathways with type 1 diabetes and selecting synergistic combinations of drugs to maximise therapeutic efficacy. We discuss how emerging multi-omics technologies, including analysis of antigen processing and presentation to adaptive immune cells, may lead to the discovery of novel biomarkers and subsequent translation into antigen-specific immunotherapies. We also discuss the potential for using artificial intelligence to create 'digital twin' models that enable rapid in silico testing of personalised agents as well as dose determination. To conclude, we discuss some limitations of artificial intelligence and machine learning, including issues pertaining to model interpretability and bias, as well as the continued need for validation studies via confirmatory intervention trials.
Insights
Artificial intelligence and machine learning accelerate type 1 diabetes (T1D) therapy development by enabling drug repurposing and personalized treatment strategies. These advanced computational methods, alongside multi-omics and digital twins, aim to overcome traditional clinical trial limitations for T1D interventions.
Area of Science:
- Immunology
- Endocrinology
- Computational Biology
- Pharmacology
Background:
- Developing therapies for type 1 diabetes (T1D) is challenging due to limited animal models, costly clinical trials, and patient heterogeneity.
- Traditional clinical trials for T1D interventions are lengthy, expensive, and often yield heterogeneous results.
- Existing research relies on placebo-controlled trials, which are time-consuming and may not fully capture therapeutic efficacy.
Purpose of the Study:
- To review emerging strategies for accelerating drug discovery and efficacy testing in type 1 diabetes.
- To explore the potential of artificial intelligence (AI) and machine learning (ML) in T1D therapeutic development.
- To discuss novel approaches including drug repurposing, combination therapies, multi-omics, and digital twins for T1D.
Main Methods:
- Review of current literature on AI/ML applications in drug discovery and T1D research.
- Analysis of emerging multi-omics technologies for biomarker discovery and immunotherapy development.
- Discussion of AI-driven 'digital twin' models for in silico testing of personalized T1D agents and dose optimization.
Main Results:
- AI and ML can significantly accelerate the identification and testing of potential T1D therapies.
- Drug repurposing and synergistic drug combinations show promise for enhancing therapeutic efficacy.
- Multi-omics technologies may yield novel biomarkers for early diagnosis and antigen-specific immunotherapies.
Conclusions:
- AI/ML, multi-omics, and digital twins offer powerful tools to overcome traditional barriers in T1D therapy development.
- These advanced approaches can facilitate personalized medicine and improve the efficiency of clinical trials.
- Further validation studies are essential to address AI/ML limitations like interpretability and bias, ensuring reliable translation to clinical practice.
Related Concept Videos
01:22Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
01:15Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
01:22Diabetes Mellitus: Type 2 and Gestational
01:16Insulin: Dosing Regimen and Adverse Effects
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
01:24Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
01:21EPS and iPS Cells in Disease Research